БоФА Секьюрити
БоФА Секьюрити запустил анализ Definium Therapeutics Inc с купной оценкой акции и цели на цене 75,00 долларов США. Акции Definium Therapeutics currently trade at $45.28, representing significant upside potential to the analyst target. Definium Therapeutics is a late-stage clinical biopharmaceutical company developing proprietary forms of psychedelic and empathogenic drugs for brain health disorders.
Recent Developments
Definium Therapeutics announced a wider second-quarter loss due to increased spending on late-stage trials and commercial preparations. Despite the financial loss, Definium Therapeutics achieved positive results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder. The study met its primary endpoint and all key secondary efficacy endpoints, showing a significant reduction in Hamilton Anxiety Rating Scale scores.
Following these results, Canaccord Genuity raised its price target for Definium Therapeutics to $64 from $58, maintaining a Buy rating. The firm acted in response to the positive trial data, which showed DT120 improved anxiety scores by 5.4 points at 12 weeks on a placebo-adjusted basis.